<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500240</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0107</org_study_id>
    <nct_id>NCT00500240</nct_id>
  </id_info>
  <brief_title>Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)</brief_title>
  <official_title>Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if intense management and control of
      blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or
      lymphoblastic lymphoma will result in decreased risk of relapse, fewer complications, and/or
      longer survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High blood sugar is a common side effect of treatment for certain types of cancer.

      You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.
      Participants in one group will receive blood sugar management with regular human insulin.
      Participants in the other group will receive more intense management with two newer forms of
      human insulin - insulin aspart, for rapid lowering of the blood glucose and insulin glargine
      for the slow decrease of blood sugar level over 24 hours.

      You will receive additional blood tests (about 1 tablespoon each) at the time of entry on the
      study and after about every 2 to 4 courses of chemotherapy while on the study. These blood
      tests help better define the severity of your high blood sugar and your body's ability to
      metabolize sugar. Any bone marrow and blood samples that were collected before your therapy
      for your leukemia may be used for lab tests to measure markers of glucose metabolism in the
      blood. You will not be required to have a bone marrow biopsy after enrollment on study.

      While in the hospital receiving chemotherapy, you will have your blood sugar checked 3 to 4
      times a day. To check your blood sugar level, you, your nurse, or a laboratory technician
      will prick your finger with a small needle and place a small drop of blood on a test strip.
      If your blood sugar is high, you will be given the appropriate amount of insulin.

      Before you begin out-patient insulin treatment, a research nurse, doctor, or diabetes
      educator will watch how you and/or your caregiver administer your insulin shots, to make sure
      that it is done correctly and safely. Once you leave the hospital, you will be required to
      check your own blood sugar 3 times a day and take insulin (either yourself or with the help
      of a health provider) up to 4 times a day while on steroid therapy and for 2 days after
      receiving steroids. On all other days you will be required to check your blood glucose once
      or twice a day and administer insulin 1 - 3 times daily. You will also need to speak with a
      nurse by phone every 1-3 days for review of blood sugar measurements and possible adjustment
      of the dose of insulin you must take.

      You will remain on the study from the time you are found to have high blood sugar levels
      until completion of your chemotherapy (about 8 months for most patients). You may be taken
      off this study at any time if you find that you are unable or unwilling to monitor your
      glucose or receive insulin shots at home.

      You will be followed for high blood sugar levels while you are receiving treatment with
      Hyper-CVAD chemotherapy regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and
      dexamethasone alternating cycles with methotrexate, cytarabine, methylprednisolone). If you
      continue to have high blood sugar after completion of this treatment, you will have continued
      follow-up either with your primary physician at home or if you choose, in the Internal
      Medicine Clinic at M. D. Anderson.

      This is an investigational study. All of the insulin used in this study is FDA approved for
      the treatment of high blood sugar and commercially available. A total of up to 114 patients
      will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to futility.
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-Year Overall Survival Rate</measure>
    <time_frame>1 year</time_frame>
    <description>The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment) up to 6 years</time_frame>
    <description>Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Date of complete remission to disease progression, assessed for approximately 6 years</time_frame>
    <description>PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count &gt;1.0 × 10^9/L, platelet count &gt;100 × 10^9/L, no abnormal peripheral blasts, and &lt;5% blasts in normocellular or hypercellular bone marrow.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Conventional Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group: Conventional care using blood sugar management with regular human insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.</description>
    <arm_group_label>Intensive Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.</description>
    <arm_group_label>Intensive Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;/= 15 years.

          2. Previously untreated ALL, Burkitt's lymphoma, or lymphoblastic leukemia receiving
             induction chemotherapy with hyper-CVAD or variants of the hyper-CVAD regimen.

          3. Random serum glucose &gt;/= 180 mg/dL detected during the first 2 cycles of chemotherapy
             and confirmed with a second measurement.

        Exclusion Criteria:

          1. History of Type I diabetes mellitus.

          2. Pregnancy or breast feeding.

          3. Allergy to insulin or insulin products.

          4. On-going treatment of steroid-induced hyperglycemia by an endocrinologist and/or
             general internist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khanh Vu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center's Website</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <results_first_submitted>June 5, 2013</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Burkitts Lymphoma</keyword>
  <keyword>Lymphoblastic Leukemia</keyword>
  <keyword>Blood Sugar</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Insulin Aspart</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Hyper-CVAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 04/27/2004 through 7/1/2008. All participants recruited at the University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Fifty-two participants were randomized to a conventional treatment arm or an intensive insulin intervention arm. One participant on the conventional control arm was excluded and did not receive allocated intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional Care</title>
          <description>Control Group: Conventional care using blood sugar management with regular human insulin.</description>
        </group>
        <group group_id="P2">
          <title>Intensive Insulin</title>
          <description>Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Care</title>
          <description>Control Group: Conventional care using blood sugar management with regular human insulin.</description>
        </group>
        <group group_id="B2">
          <title>Intensive Insulin</title>
          <description>Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="17" upper_limit="70"/>
                    <measurement group_id="B2" value="57.5" lower_limit="18" upper_limit="85"/>
                    <measurement group_id="B3" value="52" lower_limit="17" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1-Year Overall Survival Rate</title>
        <description>The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months.</description>
        <time_frame>1 year</time_frame>
        <population>There were 51 evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Care</title>
            <description>Control Group - Conventional care using blood sugar management with regular human insulin.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin</title>
            <description>Intervention Group - Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>1-Year Overall Survival Rate</title>
          <description>The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months.</description>
          <population>There were 51 evaluable participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="67" upper_limit="97.4"/>
                    <measurement group_id="O2" value="63.5" lower_limit="47" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up.</description>
        <time_frame>Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment) up to 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Care</title>
            <description>Control Group - Conventional care using blood sugar management with regular human insulin</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Deaths</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="2" upper_limit="66"/>
                    <measurement group_id="O2" value="62.2" lower_limit="0.5" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count &gt;1.0 × 10^9/L, platelet count &gt;100 × 10^9/L, no abnormal peripheral blasts, and &lt;5% blasts in normocellular or hypercellular bone marrow.</description>
        <time_frame>Date of complete remission to disease progression, assessed for approximately 6 years</time_frame>
        <population>There were 51 evaluable participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Care</title>
            <description>Control Group - Conventional care using blood sugar management with regular human insulin.</description>
          </group>
          <group group_id="O2">
            <title>Intensive Insulin</title>
            <description>Intervention Group - Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count &gt;1.0 × 10^9/L, platelet count &gt;100 × 10^9/L, no abnormal peripheral blasts, and &lt;5% blasts in normocellular or hypercellular bone marrow.</description>
          <population>There were 51 evaluable participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" lower_limit="1" upper_limit="66"/>
                    <measurement group_id="O2" value="24" lower_limit="1" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event (AE) collection from identification of high blood sugar levels until completion of chemotherapy (about 8 months). Study period was from enrollment beginning on 4/27/2004 and follow up ending on 1/20/2010.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conventional Care</title>
          <description>Control Group: Conventional care using blood sugar management with regular human insulin.</description>
        </group>
        <group group_id="E2">
          <title>Intensive Insulin</title>
          <description>Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Deaths were due to progressive disease and were not related to the study treatment.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early due to futility at the pre-determined interim analysis point.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Khanh D Vu, MD/ Associated Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-4516</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

